Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit

2021-10-12

LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) --Kaleido Biosciences (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that CEO Dan Menichella will present a company overview at the Jefferies Virtual Next Generation IBD Therapeutics Summit at 1:45PM ET on Tuesday, October 19. The webcast of the presentation will be made available in the Investors & Media section of Kaleido’s website at . An archived replay will be available for 30 days following the event. About Kaleido Biosciences Kaleido Biosciences is a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and pro the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit . Contacts: Kaleido Biosciences William Duke, Jr. Chief Financial Officer 617-890-5772 william.duke@kaleido.com Investors and Media Kotaro Yoshida Argot Partners 212-600-1902 kaleido@argotpartners.com

机构